Acute lung injury is a syndrome diagnosed clinically and is one of the most common causes of respiratory failure seen in the intensive care unit. A consensus definition of this and its more severe form, acute respiratory distress syndrome (ARDS), has allowed for better consistency in determining the epidemiology and facilitates consistent clinical trial design to better find therapies to treat or prevent it. Patients who present with ARDS usually show signs of tachpnea or dyspnea and have underlying conditions that promote inflammatory responses. The pathogenesis involves an inflammatory insult that eventually destroys the pulmonary capillary vasculature as well as alveoli. Pathophysiologically, the patient with ARDS may progress through as many as 3 phases: exudative, proliferative, and fibrotic. Treatment options can be either nonpharmacologic or pharmacologic and are limited. Ventilator strategies such as low-tidal-volume ventilation have improved outcomes in these patients, while corticosteroid use is not as established to provide morbidity or mortality benefit. Other therapies have been investigated with inconclusive or disappointing results for the treatment of this fatal syndrome.
Vincent JL, Akca S, De Mendonca A, et al.The epidemiology of acute respiratory failure in critically ill patients. Chest. 2002;121:1602-1609.
2.
Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319-323.
3.
Bernard GR, Artigas A, Brigham KL, et al.The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 pt 1):818-824.
4.
Petty TL, Ashbaugh DG. The adult respiratory distress syndrome: clinical features, factors influencing prognosis and principles of management. Chest. 1971;60:233-239.
5.
[published correction appears in Am Rev Respir Dis1989;138:720-723]
6.
Atabai K, Matthay MA. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax. 2002;57:452-458.
7.
Luhr OR, Antonsen K, Karlsson M, et al.Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med. 1999;159:1849-1861.
8.
Lieberman D, Lieberman D, Friger MD. Seasonal variation in hospital admissions for community acquired pneumonia: a 5-year study. J Infect. 1999;39:134-140.
9.
Goss CH, Brower RG, Hudson LD, Rubenfeld GD, ARDS Network. Incidence of acute lung injury in the United States. Crit Care Med. 2003;31:1607-1611.
10.
Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA. Identification of patients with acute lung injury: predictors of mortality. AmJRespirCritCareMed. 1995;152(6 pt 1):1818-1824.
11.
Luce JM. Acute lung injury and the acute respiratory distress syndrome. Crit Care Med. 1998;26:369-376.
12.
Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151(2 pt 1):293-301.
13.
Pepe PE, Potkin RT, Reus DH, Hudson LD, Carrico CJ. Clinical predictors of the adult respiratory distress syndrome. Am J Surg. 1982;144:124-130.
14.
Fowler AA, Hamman RF, Good JT, et al.Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med. 1983;98(5 pt 1):593-597.
15.
Gurka DP, Balk RA. Acute respiratory failure, including acute lung injury and ARDS. In: Parrillo JE, Dellinger RP, eds. Critical Care Medicine: Principles of Diagnosis and Management in the Adult. 2nd ed.Saint Louis, Mo: Mosby; 2001:705-723.
16.
Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1339.
17.
Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA. Identification of patients with acute lung injury: predictors of mortality. AmJRespirCritCareMed. 1995;152(6 pt 1):1818-1824.
18.
Sloane PJ, Gee MH, Gottlieb JE, et al.A multicenter registry of patients with acute respiratory distress syndrome: physiology and outcome. Am Rev Respir Dis. 1992;146:419-426.
19.
Hudson LD, Steinberg KP. Epidemiology of acute lung injury and ARDS. Chest. 1999;116:74S-82S.
20.
Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA. 1996;275:50-54.
21.
Iribarren C, Jacobs DR Jr, Sidney S, Gross MD, Eisner MD. Cigarette smoking, alcohol consumption, and risk of ARDS: a 15-year cohort study in a managed care setting. Chest. 2000;117:163-168.
22.
Moss M, Guidot DM, Steinberg KP, et al.Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med. 2000;28:2187-2192.
23.
Udobi KF, Childs E, Touijer K. Acute respiratory distress syndrome. Am Fam Physician. 2003;67:315-322.
24.
Schwarz MI, Albert RK. “Imitators” of the ARDS: implications for diagnosis and treatment. Chest. 2004;125:1530-1535.
25.
Bellingan GJ. The pulmonary physician in critical care. 6: The pathogenesis of ALI/ARDS. Thorax. 2002;57:540-546.
26.
Fulkerson WJ, MacIntyre N, Stamler J, Crapo JD. Pathogenesis and treatment of the adult respiratory distress syndrome. Arch Intern Med. 1996;156:29-38.
27.
Gunther A, Mosavi P, Heinemann S, et al.Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161(2 pt 1):454-462.
28.
Laufe MD, Simon RH, Flint A, Keller JB. Adult respiratory distress syndrome in neutropenic patients. Am J Med. 1986;80:1022-1026.
29.
Nelson S, Belknap SM, Carlson RW, et al.A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis. 1998;178:1075-1080.
30.
Nelson S, Heyder AM, Stone J, et al.A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multi-lobar pneumonia. J Infect Dis. 2000;182:970-973.
31.
Azoulay E, Darmon M, Declaux C, et al.Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med. 2002;30:781-786.
32.
Heflin AC Jr, Brigham KL. Prevention by granulocyte depletion of increased vascular permeability of sheep lung following endotoxemia. J Clin Invest. 1981;68:1253-1260.
33.
Abraham E, Carmody A, Shenkar R, et al.Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1137-L1145.
34.
Abraham E.Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195-S199.
35.
Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis. 1990;142:1250-1257.
36.
Marshall RP, Bellingan G, Webb S, et al.Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. AmJRespirCritCareMed. 2000;162:1783-1788.
37.
Martin C, Papazian L, Payan MJ, Saux P, Gouin F. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome: a study in mechanically ventilated patients. Chest. 1995;107:196-200.
38.
Chesnutt AN, Matthay MA, Tibayan FA, Clark JG. Early detection of type III procollagen peptide in acute lung injury: pathogenetic and prognostic significance. Am J Respir Crit Care Med. 1997;156(3 pt 1):840-845.
39.
Dellinger RP, Carlet JM, Masur H, et al.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.
40.
Tobin MJ. Advances in mechanical ventilation. N Engl J Med. 2001;344:1986-1996.
41.
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
42.
Stewart TE, Meade MO, Cook DJ, et al.Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med. 1998;338:355-361.
43.
Brochard L, Roudot-Thoraval F, Roupie E, et al.Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume Reduction in ARDS. AmJRespirCritCareMed. 1998;158:1831-1838.
44.
Brower RG, Shanholtz CB, Fessler HE, et al.Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med. 1999;27:1492-1498.
45.
Ranieri VM, Suter PM, Tortorella C, et al.Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999;282:54-61.
46.
Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med. 1990;16:372-377.
47.
Feihl F, Eckert P, Brimioulle S, et al.Permissive hypercapnia impairs pulmonary gas exchange in the acute respiratory distress syndrome. AmJRespirCritCareMed. 2000;162:209-215.
48.
Perret C, Feihl F. Permissive hypercapnia: from choice to unavoidable decision. Presse Med. 1996;25:1415-1416.
49.
Perret C, Feihl F. Controlled hypercapnia: a new strategy in the treatment of severe respiratory insufficiency. Bull Acad Natl Med. 1995;179:185-195.
50.
Feihl F, Perret C. Permissive hypercapnia: how permissive should we be?AmJRespirCritCareMed. 1994;150(6 pt 1):1722-1737.
51.
McIntyre RC Jr, Haenel JB, Moore FA, Read RR, Burch JM, Moore EE. Cardiopulmonary effects of permissive hypercapnia in the management of adult respiratory distress syndrome. J Trauma. 1994;37:433-438.
Amato MB, Barbas CS, Medeiros DM, et al.Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338:347-354.
54.
McIntyre RC Jr, Pulido EJ, Bensard DD, Shames BD, Abraham E. Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med. 2000;28:3314-3331.
55.
Marcy TW, Marini JJ. Inverse ratio ventilation in ARDS: rationale and implementation. Chest. 1991;100:494-504.
56.
Shanholtz C, Brower R. Should inverse ratio ventilation be used in adult respiratory distress syndrome?AmJRespirCritCare Med. 1994;149:1354-1358.
57.
Zavala E, Ferrer M, Polese G, et al.Effect of inverse I:E ratio ventilation on pulmonary gas exchange in acute respiratory distress syndrome. Anesthesiology. 1998;88:35-42.
58.
Mercat A, Titiriga M, Anguel N, Richard C, Teboul JL. Inverse ratio ventilation (I/E = 2/1) in acute respiratory distress syndrome: a six-hour controlled study. AmJRespirCritCareMed. 1997;155:1637-1642.
59.
Armstrong BW Jr, MacIntyre NR. Pressure-controlled, inverse ratio ventilation that avoids air trapping in the adult respiratory distress syndrome. Crit Care Med. 1995;23:279-285.
60.
Lessard MR, Guerot E, Lorino H, Lemaire F, Brochard L. Effects of pressure-controlled with different I:E ratios versus volume-controlled ventilation on respiratory mechanics, gas exchange, and hemodynamics in patients with adult respiratory distress syndrome. Anesthesiology. 1994;80:983-991.
61.
Mercat A, Graini L, Teboul JL, Lenique F, Richard C. Cardiorespiratory effects of pressure-controlled ventilation with and without inverse ratio in the adult respiratory distress syndrome. Chest. 1993;104:871-875.
62.
Valta P, Takala J. Volume-controlled inverse ratio ventilation: effect on dynamic hyperinflation and auto-PEEP. Acta Anaesthesiol Scand. 1993;37:323-328.
63.
Marino PL. Mechanical ventilation. In: Marino PL, ed. Patterns of Assisted Ventilation. 2nd ed.Philadelphia, Pa: Lippincott Williams &! Wilkins; 1998:chap 27.
64.
Gattinoni L, D’Andrea L, Pelosi P, Vitale G, Pesenti A, Fumagalli R. Regional effects and mechanism of positive end-expiratory pressure in early adult respiratory distress syndrome. JAMA. 1993;269:2122-2127.
65.
Gattinoni L, Pelosi P, Crotti S, Valenza F. Effects of positive endexpiratory pressure on regional distribution of tidal volume and recruitment in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151:1807-1814.
66.
Brower RG, Lanken PN, MacIntyre N, et al.Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327-336.
67.
Pelosi P, Brazzi L, Gattinoni L. Prone position in acute respiratory distress syndrome. Eur Respir J. 2002;20:1017-1028.
68.
Ward NS. Effects of prone position ventilation in ARDS: an evidence-based review of the literature. Crit Care Clin. 2002;18:35-44.
69.
Gattinoni L, Tognoni G, Pesenti A, et al.Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med. 2001;345:568-573.
70.
Krishnan JA, Brower RG. High-frequency ventilation for acute lung injury and ARDS. Chest. 2000;118:795-807.
71.
Mehta S, Lapinsky SE, Hallett DC, et al.Prospective trial of high-frequency oscillation in adults with acute respiratory distress syndrome. Crit Care Med. 2001;29:1360-1369.
72.
Derdak S, Mehta S, Stewart TE, et al.High-frequency oscillatory ventilation for acute respiratory distress syndrome in adults: a randomized, controlled trial. AmJRespirCritCareMed. 2002;166:801-808.
73.
Cartotto R, Cooper AB, Esmond JR, Gomez M, Fish JS, Smith T. Early clinical experience with high-frequency oscillatory ventilation for ARDS in adult burn patients. J Burn Care Rehabil. 2001;22:325-333.
74.
Fort P, Farmer C, Westerman J, et al.High-frequency oscillatory ventilation for adult respiratory distress syndrome: a pilot study. Crit Care Med. 1997;25:937-947.
75.
Claridge JA, Hostetter RG, Lowson SM, Young JS. High-frequency oscillatory ventilation can be effective as rescue therapy for refractory acute lung dysfunction. Am Surg. 1999;65:1092-1096.
76.
Andersen FA, Guttormsen AB, Flaatten HK. High frequency oscillatory ventilation in adult patients with acute respiratory distress syndrome: a retrospective study. Acta Anaesthesiol Scand. 2002;46:1082-1088.
77.
Kaisers U, Kelly KP, Busch T. Liquid ventilation. Br J Anaesth. 2003;91:143-151.
78.
Gauger PG, Pranikoff T, Schreiner RJ, Moler FW, Hirschl RB. Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome. Crit Care Med. 1996;24:16-22.
79.
Greenspan JS, Wolfson MR, Rubenstein SD, Shaffer TH. Liquid ventilation of human preterm neonates. J Pediatr. 1990;117(1 pt 1):106-111.
80.
Hirschl RB, Croce M, Gore D, et al.Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. AmJRespirCritCareMed. 2002;165:781-787.
81.
Peek GJ, Moore HM, Moore N, Sosnowski AW, Firmin RK. Extracorporeal membrane oxygenation for adult respiratory failure. Chest. 1997;112:759-764.
82.
Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirschl RB. Extracorporeal life support: the University of Michigan experience. JAMA. 2000;283:904-908.
83.
Peek GJ, White S, Scott AD, et al.Severe acute respiratory distress syndrome secondary to acute pancreatitis successfully treated with extracorporeal membrane oxygenation in three patients. Ann Surg. 1998;227:572-574.
84.
Zwischenberger JB, Conrad SA, Alpard SK, Grier LR, Bidani A. Percutaneous extracorporeal arteriovenous CO2 removal for severe respiratory failure. Ann Thorac Surg. 1999;68:181-187.
85.
Reng M, Philipp A, Kaiser M, Pfeifer M, Gruene S, Schoelmerich J. Pumpless extracorporeal lung assist and adult respiratory distress syndrome. Lancet. 2000;356:219-220.
86.
Dunser M, Hasibeder W, Rieger M, Mayr AJ. Successful therapy of severe pneumonia-associated ARDS after pneumonectomy with ECMO and steroids. Ann Thorac Surg. 2004;78:335-337.
87.
Kopp R, Henzler D, Dembinski R, Kuhlen R. Extracorporeal membrane oxygenation by acute respiratory distress syndrome. Anaesthesist. 2004;53:168-174.
88.
Weigelt JA, Norcross JF, Borman KR, Snyder WH III. Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536-540.
89.
Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62-68.
90.
Bernard GR, Luce JM, Sprung CL, et al.High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565-1570.
91.
Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC Jr, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome?Am J Surg. 1995;170:591-595.
92.
Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome: diagnosis and treatment. Arch Surg. 1985;120:530-535.
93.
Hooper RG, Kearl RA. Established adult respiratory distress syndrome successfully treated with corticosteroids. South Med J. 1996;89:359-364.
94.
Meduri GU, Chinn AJ, Leeper KV, et al.Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest. 1994;105:1516-1527.
95.
Meduri GU, Headley AS, Golden E, et al.Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159-165.
96.
Lewis JF, Brackenbury A. Role of exogenous surfactant in acute lung injury. Crit Care Med. 2003;31(suppl 4):S324-S328.
97.
Spragg RG, Gilliard N, Richman P, et al.Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest. 1994;105:195-202.
98.
Walmrath D, Gunther A, Ghofrani HA, et al.Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. AmJRespirCritCareMed. 1996;154:57-62.
99.
Wiswell TE, Smith RM, Katz LB, et al.Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. AmJRespirCritCareMed. 1999;160:1188-1195.
100.
Walmrath D, Grimminger F, Pappert D, et al.Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J. 2002;19:805-810.
101.
Spragg RG, Lewis JF, Wurst W, et al.Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. AmJRespirCritCareMed. 2003;167:1562-1566.
102.
Anzueto A, Baughman RP, Guntupalli KK, et al.Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med. 1996;334:1417-1421.
103.
Gregory TJ, Steinberg KP, Spragg R, et al.Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:1309-1315.
104.
Spragg RG, Lewis JF, Walmrath D, et al.Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351:884-892.
105.
Nathens AB, Neff MJ, Jurkovich GJ, et al.Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg. 2002;236:814-822.
106.
Gadek JE, DeMichele SJ, Karlstad MD, et al.Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and anti-oxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med. 1999;27:1409-1420.
107.
Nelson JL, DeMichele SJ, Pacht ER, Wennberg AK, Enteral Nutrition in ARDS Study Group. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants on antioxidant status in patients with acute respiratory distress syndrome. JPEN J Parenter Enteral Nutr. 2003;27:98-104.
108.
Pacht ER, DeMichele SJ, Nelson JL, Hart J, Wennberg AK, Gadek JE. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med. 2003;31:491-500.
109.
Mancuso P, Whelan J, DeMichele SJ, Snider CC, Guszcza JA, Karlstad MD. Dietary fish oil and fish and borage oil suppress intrapulmonary proinflammatory eicosanoid biosynthesis and attenuate pulmonary neutrophil accumulation in endotoxic rats. Crit Care Med. 1997;25:1198-1206.
110.
Mancuso P, Whelan J, DeMichele SJ, et al.Effects of eicosapentaenoic and gamma-linolenic acid on lung permeability and alveolar macrophage eicosanoid synthesis in endotoxic rats. Crit Care Med. 1997;25:523-532.
111.
Michael JR, Barton RG, Saffle JR, et al.Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998;157(5 pt 1):1372-1380.
112.
Troncy E, Collet JP, Shapiro S, et al.Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. AmJRespirCritCareMed. 1998;157(5 pt 1):1483-1488.
113.
Dellinger RP, Zimmerman JL, Taylor RW, et al.Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26:15-23.
114.
Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 1999;25:911-919.
115.
Taylor RW, Zimmerman JL, Dellinger RP, et al.Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291:1603-1609.
116.
Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002;30:2175-2182.
117.
Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med. 2004;32:755-759.
118.
Tamakuma S, Shiba T, Hirasawa H, Ogawa M, Nakashima M. A phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients. J Clin Ther Med (Japan). 1998;14:289-318.
119.
Zeiher BG, Artigas A, Vincent J, et al.Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695-1702.
120.
Bernard GR, Wheeler AP, Russell JA, et al.The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336:912-918.
121.
Arons MM, Wheeler AP, Bernard GR, et al.Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med. 1999;27:699-707.
122.
Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987;317:659-665.
123.
Sprung CL, Peduzzi PN, Shatney CH, et al.Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. Crit Care Med. 1990;18:801-806.
124.
Slotman GJ, Burchard KW, D’Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. JTrauma. 1988;28:648-654.
125.
Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med. 1993;21:1635-1642.
126.
Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care. 1999;14:1-6.
127.
Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA. 2000;283:1995-2002.
128.
Laurent T, Markert M, Feihl F, Schaller MD, Perret C. Oxidant-antioxidant balance in granulocytes during ARDS: effect of N-acetylcysteine. Chest. 1996;109:163-166.
129.
Bernard GR, Wheeler AP, Arons MM, et al.A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112:164-172.
130.
Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med. 1992;20:918-923.
131.
Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190-194.
132.
Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. JCritCare. 1997;12:177-182.
133.
Bernard GR, Wheeler AP, Arons MM, et al.A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112:164-172.
134.
Michetti C, Coimbra R, Hoyt DB, Loomis W, Junger W, Wolf P. Pentoxifylline reduces acute lung injury in chronic endotoxemia. J Surg Res. 2003;115:92-99.
135.
Montravers P, Fagon JY, Gilbert C, Blanchet F, Novara A, Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest. 1993;103:1017-1022.
136.
Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. Crit Care Med. 2002;30:1-6.
137.
Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome: a prospective trial. Ann Surg. 1986;203:371-378.
138.
Vassar MJ, Fletcher MP, Perry CA, Holcroft JW. Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients: a prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation. Prostaglandins Leukot Essent Fatty Acids. 1991;44:223-231.
139.
Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. AmJRespirCritCareMed. 1998;157(6 pt 1):1743-1747.
140.
Vincent JL, Brase R, Santman F, et al.A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 2001;27:1578-1583.
141.
Abraham E, Baughman R, Fletcher E, et al.Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999;27:1478-1485.
142.
Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. AmJRespirCritCareMed. 1996;153:991-996.
143.
Zwissler B, Kemming G, Habler O, et al.Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. AmJRespirCritCareMed. 1996;154(6 pt 1):1671-1677.
144.
Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS—a pilot study. Anaesth Intensive Care. 1996;24:564-568.
145.
Wysocki M, Delclaux C, Roupie E, et al.Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intensive Care Med. 1994;20:254-259.
146.
Lu Q, Mourgeon E, Law-Koune JD, et al.Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology. 1995;83:929-943.
147.
Jolliet P, Bulpa P, Ritz M, Ricou B, Lopez J, Chevrolet JC. Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome. Crit Care Med. 1997;25:786-794.
148.
B’Chir A, Mebazaa A, Losser MR, Romieu M, Payen D. Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury. Anesthesiology. 1998;89:823-830.
149.
Paven D, Muret J, Beloucif S, et al.Inhaled nitric oxide, almitrine infusion, or their coadministration as a treatment of severe hypoxemic focal lung lesions. Anesthesiology. 1998;89:1157-1165.
150.
Gallart L, Lu Q, Puybasset L, Umamaheswara Rao GS, Coriat P, Rouby JJ. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitrine Study Group. AmJRespirCritCareMed. 1998;158:1770-1777.
151.
Gillart T, Bazin JE, Cosserant B, et al.Combined nitric oxide inhalation, prone positioning and almitrine infusion improve oxygenation in severe ARDS. Can J Anaesth. 1998;45(5 pt 1):402-409.
152.
Papazian L, Bregeon F, Gaillat F, et al.Inhaled NO and almitrine bismesylate in patients with acute respiratory distress syndrome: effect of noradrenalin. Eur Respir J. 1999;14:1283-1289.
153.
Michard F, Wolff MA, Herman B, Wysocki M. Right ventricular response to high-dose almitrine infusion in patients with severe hypoxemia related to acute respiratory distress syndrome. Crit Care Med. 2001;29:32-36.
